The Menarini Group has had a long-standing interest in the identification and targeting of the molecular drivers of cancers and delivering personalized treatments of the highest specificity and bioactivity for patients with cancer. As the landscape of medical oncology evolves, the focus has shifted from the use of nonspecific cytotoxic treatment strategies toward the delivery of targeted therapies. These therapies is developed on the basis of specific molecular characteristics of the tumor and unique clinical features of the individual patient. Given that most cancers tend to be complex, even when they exhibit a unique molecular signature, to be ‘precise’ we need to ‘personalize’ our approach. Targeted cancer therapy involves small molecules and antibodies that recognize targets expressed by cancer cells, and may improve the survival of patients with fewer side effects versus conventional chemotherapy approaches.
At Menarini, we are currently investigating a broad range of cancer targets and are developing multitargeted and biomarker-selected inhibitors in tandem with developing techniques for analyzing tumor DNA, in tissue and liquid biopsies, to detect, characterize and monitor cancer. We recognize cancer’s ability to continuously evolve and adapt, and our oncology researchers and drug development teams are tasked with helping to predict future directions to outpace the disease and deliver optimal cancer care. Menarini recognizes the continuous advances in the field of precision medicine and the impressive diagnostic and treatment options to improve efficacy and cost-effectiveness. We now stand at the threshold of multiple changes which will determine how precision medicine will define twenty-first century cancer therapeutics.